Price movement over the last 24 hours
Alcon AG vs Ishares Msci Italy ETF — how do they compare? Alcon AG trades at $66.95 (market cap $32.69B), while Ishares Msci Italy ETF trades at $59.95. The key difference: Alcon AG pays a 0.54% dividend while Ishares Msci Italy ETF pays none, and Ishares Msci Italy ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | EWI | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $92.22 | $61.14 |
52-Week Low | $62.02 | $47.32 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
EWI trades at $61.14, up 0.84% today, with a bullish technical signal driven by moving averages. The stock recently hit a 52-week high (Zacks Investment Research, 2026-06-10), supported by improving Italian industrial data. A dividend of $1.17 is scheduled for payment on June 18, 2026. However, key valuation ratios like P/E and P/S are unavailable, limiting fundamental clarity.
Outlook is mixed: technical strength and European equity inflows (Proactive Investors, 2026-07-07) offer upside, but stagflation risks in Italy (Seeking Alpha, 2026-06-04) and ECB rate hikes (Bloomberg, 2026-06-11) pose headwinds. Investors should weigh bullish momentum against macroeconomic uncertainties and incomplete financial data.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →